These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 3121169)
1. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169 [TBL] [Abstract][Full Text] [Related]
2. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164 [TBL] [Abstract][Full Text] [Related]
3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474 [TBL] [Abstract][Full Text] [Related]
4. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813 [TBL] [Abstract][Full Text] [Related]
5. Acute in vivo resistance in high-dose therapy. Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913 [TBL] [Abstract][Full Text] [Related]
7. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide. Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483 [TBL] [Abstract][Full Text] [Related]
8. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo. Donnelly ET; Kelley M; Rockwell S Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460 [TBL] [Abstract][Full Text] [Related]
9. Preclinical studies and clinical correlation of the effect of alkylating dose. Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059 [TBL] [Abstract][Full Text] [Related]
10. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott WL; Roberts BJ; Howard CT; Leopold WR Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790 [TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor PS-341 in cancer therapy. Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643 [TBL] [Abstract][Full Text] [Related]
13. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001 [TBL] [Abstract][Full Text] [Related]
14. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow. Ono K; Shrieve DC J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662 [TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of combination drug purging for autologous bone marrow transplantation. Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626 [TBL] [Abstract][Full Text] [Related]
16. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
17. Influence of scheduling on two-drug combinations of alkylating agents in vivo. Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139 [TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296 [TBL] [Abstract][Full Text] [Related]
19. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481 [TBL] [Abstract][Full Text] [Related]
20. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio. Rockwell S; Nierenburg M; Irvin CG Cancer Treat Rep; 1987 Oct; 71(10):927-34. PubMed ID: 3652056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]